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vivo	 intracoronary	 gene	 transfer	 of	 adeno-associated	 virus	 2	 leads	 to	 superior	
transduction	 over	 serotypes	 8	 and	 9	 in	 rat	 heart	 transplants.	 Transpl	 Int.	 2013	
Nov;26(11):1126–37.	
	
II. Raissadati	 A*,	 Tuuminen	 R*,	 Dashkevich	 A,	 Bry	M,	 Kivelä	 R,	 Anisimov	 A,	 Syrjälä	 SO,	
Arnaudova	R,	Rouvinen	E,	Keränen	MA,	Krebs	R,	Nykänen	AI,	Lemström	KB.	Vascular	
endothelial	growth	factor-B	overexpressing	hearts	are	not	protected	from	transplant-











AAV		 	 –	 Adeno-associated	virus	
Ag	 	 –	 Antigen	
Amp	 	 –	 ampicillin-resistant	
APC	 	 –	 Antigen-presenting	cell	
ATP	 	 –	 Adenosine	triphosphate	
CAV	 	 –	 Cardiac	allograft	vasculopathy	
CBP	 	 –	 Creb	binding	protein	
CD	 	 –	 Cluster	of	differentiation	
Cl	 	 –	 Confidence	interval	
CMC	 	 –	 Cardiomyocyte	
CMV	 	 –	 Cytomegalovirus	
CTAD	 	 –	 C	terminal	transactivation	domain	
DAMP	 	 –	 Damage-associated	molecular	pattern	
DC	 	 –	 Dendritic	cell	
EC	 	 –	 Endothelial	cell	
FIH	 	 –	 Factor	inhibiting	HIF-1	
HIF	 	 –	 Hypoxia-inducible	factor	
HLA	 	 –	 Human	leukocyte	antigen	
HR	 	 –	 Hazard	ratio	
HTx	 	 –	 Heart	transplantation	
IC	 	 –	 Intracoronary	
ICAM	 	 –	 Intercellular	adhesion	molecule	
ILC	 	 –	 Innate	lymphoid	cell	
IRI	 	 –	 Ischemia-reperfusion	injury	
ITR	 	 –	 Inverted	terminal	repeats	
IV	 	 –	 Intravenous	
KIR	 	 –	 Killer	cell	immunoglobulin-like	receptor	
KO	 	 –	 Knock-out	
LEC	 	 –	 Lymphatic	endothelial	cell	
M1	 	 –	 Classically	activated	macrophage	
M2	 	 –	 Alternatively	activated	macrophage	
MDSC	 	 –	 Myeloid-derived	suppressor	cell	
MHC	 	 –	 Major	histocompatibility	complex	
MPO	 	 –		 Myeloperoxidase	
MPTP	 	 –	 Mitochondrial	permeability	transition	pore	
MSC	 	 –	 Mesenchymal	stromal	cells	
NK	 	 –	 Natural	killer	
NRP	 	 –	 Neuropilin	
ORF	 	 –	 Open	reading	frame	
ORI	 	 –	 Origin	of	replication	
PAMP	 	 –	 Pathogen-associated	molecular	pattern	
PDGF	 	 –	 Platelet-derived	growth	factor	
PHD	 	 –	 4-prolyl	hydroxylase	
PlGF	 	 –	 Placental	growth	factor	
PRR	 	 –	 Pattern	recognition	receptor	
rAAV	 	 –	 Recombinant	Adeno-associated	virus	
RIG	 	 –	 Retinoic	acid-inducible	gene	
ROS	 	 –	 Reactive	oxygen	species	
VEC	 	 –	 Vascular	endothelial	cell	
VEGF	 	 –	 Vascular	endothelial	growth	factor	
VEGFR	 	 –	 Vascular	endothelial	growth	factor	receptor	
VHL	 	 –	 Von	Hippel	Lindau	protein	
TAM	 	 –	 Tumor-associated	macrophage	
TAN	 	 –	 Tumor-associated	neutrophil	
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TCR	 	 –	 T-cell	receptor	
TLR	 	 –	 Toll-like	receptor	
TNT	 	 –	 Troponin	T	
TREM	 	 –	 Triggering	receptor	expressed	on	myeloid	cells	
TX-IRI	 	 –	 Transplant-associated	ischemia-reperfusion	injury	
Treg	 	 –	 Regulatory	T	cell	
Tr1	 	 –	 T	regulatory	type	1	cell	
WPRE	 	 –	 Woodchuck	hepatitis	virus	post-transcriptional	regulatory	element	




Arg	 	 –	 Arginase	
CCL	 	 –	 Chemokine	(C-C	motif)	ligand	
CCR	 	 –	 Chemokine	(C-C	motif)	receptor	
CTLA	 	 –	 Cytotoxic	T	lymphocyte	associated	protein	
CXCL	 	 –	 Chemokine	(C-X-C	motif)	ligand	
CXCR	 	 –	 Chemokine	(C-X-C	motif)	receptor	
DNAM	 	 –	 DNAX	accessory	molecule	
FOXp3	 	 –	 Forkhead	box	P3	
GARP	 	 –	 Glycoprotein	A	repetitions	predominant	
GAL	 	 –	 Galectin	
G-CSF	 	 –	 Granulocyte	colony-stimulating	factor	
GM-CSF	 	 –	 Granulocyte-macrophage	colony-stimulating	factor	
IDO	 	 –	 Indoleamine	2,3-dioxygenase	
IFN	 	 –	 Interferon	
IL	 	 –	 Interleukin	
IP	 	 –	 Interferon	gamma	induced	protein	
iNOS	 	 –	 Inducible	nitric	oxide	synthase	
LAG	 	 –	 Lymphocyte	activation	gene	
MIG	 	 –	 Monokine	induced	by	gamma	interferon	
MMP	 	 –	 Matrix	metalloproteinase	
M-CSF	 	 –	 Macrophage	colony	stimulating	factor	
NO	 	 –	 Nitric	oxide	
iNOS	 	 –	 Inducible	nitric	oxide	synthase	
PGE2	 	 –	 Prostaglandin	E2	
sGC	 	 –	 Soluble	guanylyl	cyclase	
TGF	 	 –	 Transforming	growth	factor	
TL1A	 	 –	 Tumor	necrosis	factor-like	cytokine	1A	
TNF	 	 –	 Tumor	necrosis	factor	

























injection,	whereas	 AAV9	was	most	 effective	when	 injected	 systemically	 into	 the	 transplant	
donor.	 Adeno-associated	 virus	 serotype	 9	 caused	 a	mild	 inflammatory	 response	 in	 cardiac	
allografts,	whereas	AAV2	and	8	did	not.	Chronic,	but	not	short-term,	VEGF-B	overexpression	in	
rat	 cardiac	 transplants	 resulted	 in	 cardiomyocyte	hypertrophy	 and	higher	 energy	demands,	








ischemic	 tolerance.	 Hypoxia-inducible	 factor-1α	 and	 -2α	 act	 as	 important	 switches	 for	 the	







discovered	 that	 the	 one	 overwhelming	 obstacle	 towards	 long-term	 survival	 of	 organ	
transplants	was	the	immune	response	of	the	recipient.	Accumulated	evidence	from	research,	
however,	has	broadened	our	knowledge	of	the	underlying	problem	to	not	only	immunologic	
factors,	 but	 also	 non-immunologic	 insults	 to	 the	 transplanted	 tissue	 during	 brain	 death,	
procurement,	preservation,	and	reperfusion	of	the	organs.1,2	We	have	now	come	to	understand	
that	 the	 earliest	 insults	 to	 the	 transplant	 stimulate	 the	 recipient	 innate	 immune	 system	 to	




heart	 transplant	 recipients	 are	 screened	with	 endomyocardial	 biopsies	 and	 coronary	 artery	
angiograms.	These	highly	 invasive	diagnostic	modalities	burden	the	patients	with	potentially	
serious	 complications.	 Patients	 require	 life-long	multidrug	 immunosuppressive	 regimens	 to	
prevent	 the	 rejection	 of	 their	 transplant,	 exposing	 them	 to	 harmful	 side-effects	 and	
opportunistic	 infections	that	may	give	rise	to	compliancy	concerns.	These	 issues	necessitate	
new	both	diagnostic	and	therapeutic	modalities.	One	prominent	method	is	gene	therapy.	The	
method	uses	viral	 vectors	 to	 introduce	exogenous	genetic	material	 into	specific	 tissues	and	
cells.	It	could	potentially	eliminate	the	need	for	invasive	diagnostic	methods	and	harmful	drug	
side-effects	by	using	suitable	promoters	that	activate	vector-carried	reporter-	or	therapeutic	
genes	 in	 a	 tissue-specific	 manner.	 Adeno-associated	 viruses	 (AAV)	 are	 among	 the	 most	
researched	viral	vectors	due	to	their	low	pathogenicity	and	high	transductivity.3		
	
After	brain	death,	one	of	the	earliest	 insults	to	the	transplant	 is	 ischemia	during	the	ex	vivo	
preservation	and	 subsequent	 reperfusion	after	 implantation	 into	 the	 recipient.	 The	hypoxic	
environment	and	the	ensuing	inflammation	activate	several	innate	molecular	pathways.	Among	
the	best	characterized	ones	are	hypoxia-inducible	factors	(HIF)	and	vascular	endothelial	growth	
factors	 (VEGF).	 Hypoxia-inducible	 factors	 are	 transcriptional	 regulators	 that	 allow	 cell	
adaptation	to	hypoxic	environments	by	regulating	a	wide	set	of	metabolic-,	angiogenic-,	and	
inflammatory	 genes.4	 The	 VEGF	 family	 comprises	 VEGF-A,	 -B,	 -C,	 –D,	 and	 -E	 with	 their	























performed	 by	 Dr.	 William	 Bernhard	 in	 Boston	 Children’s	 Hospital.10,11	 The	 first	






The	 number	 of	 heart	 transplantations	 have	 increased	 steadily	 throughout	 the	 years,	 with	
current	rates	of	close	to	4,500	procedures	annually.13	The	development	of	cardiac	inotropes	
and	mechanical	 assist	 devices	have	allowed	medical	 teams	 to	bridge	 their	 patients	 to	 their	
transplantation,	prolonging	patient	 lives	and	subsequently	also	 transplant	waiting	 list	 times.	
Consequently,	many	transplantation	programs	have	adapted	donor	extended	criteria,	such	as	
prolonged	>4-hour	 ischemia	 times,	 age	>55	 years,	 abnormal	 ECG,	diabetes,	 chronic	 alcohol	






maintenance	 therapy.	 Induction	 therapy	 is	 used	 in	 ca.	 50%	 of	 cases,	 and	most	 commonly	
consists	 of	 rabbit	 antithymocyte	 immunoglobulin	 or	 IL-2	 receptor	 antagonist	 basiliximab.	
Maintenance	therapy	is	chosen	on	an	individual	basis,	and	usually	combines	a	triple	therapy	of	
calcineurin	inhibitor,	corticosteroid,	and	a	cell	cycle	inhibitor.	Tacrolimus	is	the	most	preferred	








































of	 norepinephrine	 and	 neuropeptide	 y	 from	 the	 adrenal	 medulla,	 but	 also	 locally	 in	 the	
myocardium	 via	 sympathetic	 innervation.22,23	 Experimental	 models	 refuting	 correlation	
between	cardiac	troponin	I	and	systemic	catecholamine	levels	after	cardiac	sympathectomy	in	
baboons	 suggest	 a	 more	 critical	 role	 of	 the	 local	 release	 of	 catecholamines	 in	 mediating	
myocardial	 damage.24	 The	 effect	 is	 profound	 systemic	 hypertension,	 increased	 vascular	
resistance,	intense	coronary	vasospasm,	and	arrhythmias,	causing	myocardial	ischemia,	release	
of	reactive	oxygen	species	(ROS),	irreversible	contraction	band	stretching,	and	cell	death.24,25	







leads	 to	 enhanced	anaerobic	metabolism,	metabolic	 acidosis,	 and	 tissue	hypothermia,	with	
their	corresponding	negative	myocardial	repercussions.29	
	
Inflammatory	 reaction	 –	 Ischemia	 and	hemodynamic	 alterations	 lead	 to	 enhanced	 cytokine	
release	from	the	brain,	intestines,	and	activated	vascular	endothelial	cells	(VEC).	Upregulated	
cytokines	 include	TNF-α,	 IFN-g,	 IL-1α	and	–β,	 IL-2,	 IL-2Rb,	CCL2,	and,	most	 importantly,	 IL-6.	
Activation	of	the	VEC	leads	to	upregulation	of	ICAM-1,	VCAM-1,	P-,	and	E-selectin.30	Also,	brain	
death	 upregulates	 the	 expression	 of	 major	 histocompatibility	 complex	 II	 antigens.21	 This	
systemic	 and	 local	 pro-inflammatory	 state	 increases	 the	 immunogenicity	 of	 the	 heart	
















production	 and	 leads	 to	 cellular	 swelling,	 membrane	 rupture,	 and	 cell	 death	 via	 necrosis,	
apoptosis,	necroptosis,	and	autophagy.33,34	This	results	in	release	of	intracellular	immunogenic	
damage-associated	molecules	(DAMPs),	which	later	prove	detrimental	in	activating	the	innate	






























Na+-HCO3	 pumps	 results	 in	 an	 abrupt	 correction	 of	 intracellular	 pH	 and	 subsequent	MPTP	
opening	and	CMC	hypercontracture.44,45	
	
Microvascular	 dysfunction	 and	 inflammation	 –	 reperfusion	 injury	 results	 in	 microvascular	
leakage	through	destabilization	of	the	vascular	wall	and	formation	of	EC-EC	gaps.46-48	One	of	
the	 main	 mechanisms	 behind	 reperfusion-mediated	 microvascular	 dysfunction	 is	 oxidant-
induced	 early	 leukocyte-EC	 interactions.40,49,50	 These	 include	 ROS-mediated	 release	 of	
	 15	
proinflammatory	 cytokines	 and	 chemokines	 by	 the	 EC	 (such	 as	 IL-1	 and	 TNF-α),	 local	
parenchymal	cells,	and	infiltrating	leukocytes;	expression	of	adhesion	molecules	on	activated	
EC	and	leukocytes	(CD11/CD18	integrins,	ICAM-1,	and	P-selectin);	and	depletion	of	endothelial	
nitric	 oxide	 (NO).51-55	 This	 combined	with	 the	 ischemia-induced	 decline	 in	 EC	 NO	 synthase	
(iNOS)	 activity	 and	 oxidation	 of	 soluble	 guanylyl	 cyclase	 (sGC)	 serves	 to	 amplify	 the	
inflammatory	response.	Host	leukocytes,	mostly	neutrophils,	form	adhesive	interactions	with	
the	activated	EC	in	postcapillary	venules,	migrate	into	the	tissue,	and	start	releasing	oxidants	
and	 hydrolytic	 enzymes	 that	 damage	 the	 parenchymal	 tissue	 and	mediate	 EC	 and	 pericyte	
dysfunction.	 The	 damage	 on	 both	 intra-	 and	 intercellular	 cytoskeletal	 components	 and	
contraction	 of	 EC	 disrupt	 tight-	 and	 adherens	 junctions	 of	 the	 vascular	 wall,	 leading	 to	 EC	
blebbing	and	the	formation	of	EC-EC	gaps,	vascular	leakage,	and	influx	of	host	leukocytes.46-48	
	
Ischemia-reperfusion	 injury	 activates	 both	 the	 vascular-	 and	 the	 lymphatic	 endothelium	
(LEC).56,57	The	former	mediates	leukocyte	entry	after	reperfusion,	and	the	latter	leukocyte	exit	
early	 after	 transplantation.	 Also,	 the	 hypoxic	 environment	 has	 been	 shown	 to	 affect	 the	





The	 innate	 immune	 response	 is	 the	 body’s	 first	 line	 of	 surveillance	 and	 defense	 against	
imminent	threats.	The	cellular	arm	comprises	neutrophils,	monocytes,	macrophages,	dendritic	








The	cellular	arm	of	 the	 innate	 immune	system	 is	equipped	with	 special	pattern	 recognition	
receptors	 (PRR),	 of	 which	 toll-like	 receptors	 (TLR),	 particularly	 TLR-4	 in	 the	 setting	 of	
Figure	2	–	Cells	of	the	immune	system	relevant	to	transplantation.	APC,	antigen	presenting	cells.	
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transplantation,	 are	 the	 hallmark.58,59	 These	 receptors	 provide	 immune	 cells	 the	means	 to	


























especially	 free	 radicals,	 significantly	 prolonged	 renal	 allograft	 survival.63	 These	 findings	


































proliferate	 and	 are	 mobilized	 from	 the	 bone	marrow	 in	




CXCL,	 chemokine	 (C-X-C	 motif)	 ligand;	 CCL,	 chemokine	 (C-C	 motif)	 ligand;	 IL,	 interleukin;	 IFN,	 interferon;	 MIF,	 migration	
inhibitory	factor;	G-CSF,	granulocyte	colony-stimulating	factor;	GM-CSF,	granulocyte-macrophage	colony-stimulating	factor;	














PRRs,	 such	 as	 ficolins	 and	 pentraxins	 that	 activate	 the	 complement	 system	 and	 enhance	






















tissue-specific	 phagocytes,	 such	 as	 Kupffer	 cells,	 osteoclasts,	 and	 alveolar	 macrophages.	
Circulating	monocytes	have	an	estimated	half-life	of	70h.	Accumulating	evidence	has	revealed	





CCL,	 chemokine	 (C-C	 motif)	 ligand;	 CXCL,	 chemokine	 (C-X-C	 motif)	 ligand;	 MIP,	 macrophage	 inflammatory	 protein;	 MIG,	
monocyte	induced	by	interferon	gamma;	IP,	interferon-gamma-inducible	protein;	IL,	interleukin;	TNF,	tumor-necrosis	factor;	




Tissue-resident	 macrophages	 and	 the	 first	 monocytes	 to	 reach	 the	 site	 of	 injury	 are	 not	
sufficient	to	mount	a	full	immune	response.	Instead,	they	secrete	chemokines	and	proliferation	
signals,	such	as	G-CSF,	CCL2,	and	CCL5	to	mobilize	additional	monocytes	and	macrophages	from	
the	 bone	 marrow	 and	 spleen	 to	 the	 site	 of	 inflammation	 (Table	 3).	 Macrophages	 act	 as	
patrolling	 cells	 of	 the	 tissues.	 They	 are	 activated	 by	 PRR	 ligation	 or	 IFN-g;	 phagocytose	
pathogens,	foreign	material,	and	necrotic	cells;	and	belong	to	the	APC	family	of	leukocytes.75	













are	 divided	 into	 classical	 and	 nonclassical	 (pre-dendritic	 cell)	 DC.	 Classical	 DCs	 comprise	
CD8α+/CD103α+	 and	 CD11b+	 DCs,	 and	 nonclassical	 ones	 include	 monocyte-derived	 and	














Like	macrophages,	DCs	may	migrate	via	both	 the	blood	and	 lymphatic	 system,	 the	 latter	of	
which	has	been	suggested	as	an	important	route	for	exiting	the	heart	and	tracheal	transplants	







foreign	 and	 eliminated.84,85	 In	 addition	 to	 foreign	 non-self	 cells,	MHC	 I	 dissipates	 from	 the	
surface	of	unhealthy	and	dying	cells,	rendering	them	targets	for	destruction	by	NK	cells.	The	




































type	 antigen-specific	 defense	 mechanism	
against	 non-self	 insults	 to	 the	 body.	 The	
cellular	 arm	 comprises	 T	 cells	 and	 the	
humoral	 arm	 B	 cells	 and	 their	 secreted	
antigen-specific	 antibodies.	 All	 cells	 of	 the	
adaptive	 immune	 system	 stem	 from	 a	



































secondary	 lymphoid	 organs,	 most	 commonly	 in	 lymph	 nodes.	 Their	 function	 is	 highly	
dependent	on	T	cell	activation	and	stimulation,	upon	which	they	differentiate	into	plasma	cells	









iTreg,	 inducible	 regulatory	 T	 cell;	 TGF,	 transforming	 growth	 factor;	 TNF,	 tumor	
necrosis	factor.	
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by	 donor	 passenger	 leukocytes	 and	 ECs	 provide	 the	 necessary	 means	 for	 an	 effective	
immunological	 response	 to	 develop.54,56,57,116-124	 Thus,	 the	 cardiac	 allograft	 is	 primed	 for	
inflammation	prior	 to	 implantation	 into	the	recipient.	What	 follows	after	reperfusion,	 is	 the	
activation	 and	 influx	 of	 innate	 immune	 cells	 into	 the	 allograft,	 memory	 T	 cell	 infiltration,	
allorecognition,	 and	 activation	 and	 proliferation	 of	 a	 de	 novo	 adaptive	 immune	 response.2	
Other	 both	 immunological	 and	 non-immunological	 factors,	 such	 as	 the	 degree	 of	 genetic	













on	APCs,	and	 is	 recognized	by	CD4+	T	cells.114	The	polygenic,	 codominant,	and	polymorphic	
expression	 of	 the	 HLA	 genes	 ensures	 diverse	 antigen	 presentation.	 Nevertheless,	 in	
transplantation,	 this	 diversity	 is	 the	 greatest	 contributor	 to	 tissue	 mismatch,	 as	 recipient	
immune	cells	recognize	allogeneic	donor	mismatched	MHC-molecules	as	foreign	antigens	 in	
the	process	of	allorecognition	(see	later).	In	the	case	of	syngeneic	transplants,	such	as	those	
between	 twins,	 this	allorecognition	does	not	occur	due	 to	 the	MHC-matched	 tissues	of	 the	
donor	and	recipient.	However,	although	MHC	mismatch	is	the	main	decisive	factor	for	allograft	
rejection,	minor	histocompatibility	antigens	are	also	capable	of	activating	the	adaptive	immune	
response,	 as	 witnessed	 in	 transplantation	 between	 MHC-matched	 siblings.115	 Minor	
histocompatibility	antigens	represent	normal	proteins	with	a	variable	degree	of	polymorphism	




























Natural	 killer	 cells	 have	 also	 recently	 been	 implicated	 as	 important	 mediators	 of	 allograft	




independently	 of	 the	 adaptive	 immune	 system	 in	 the	 presence	 of	 exogenous	 IL-15	
stimulation.146	
	
After	 initial	 allograft	 infiltration,	 monocytes	 differentiate	 into	 macrophages.	 Damage-
associated	molecular	patterns	such	as	haptoglobin,	HMGP1,	ROS,	extracellular	ATP,	heat	shock	
proteins,	hyaluronan,	and	sialic	acid	are	sensed	by	the	PRR,	particularly	TLR4,	of	innate	immune	
cells,	 leading	 to	 activation	 of	 NF-κB	 and	 the	 inflammasome.137,147-149	 Subsequently,	 further	
production	and	secretion	of	proinflammatory	cytokines	and	chemokines	ensues,	exacerbating	
the	acute	inflammatory	reaction.	Also,	the	production	of	chemokines	and	growth	factors,	such	












during	 late	 acute	 rejection,	which	plays	 a	 significant	 role	 in	 the	 recruitment	 of	 alloantigen-
primed	 T	 cells	 to	 the	 allograft.150,151	 Donor	 passenger	 leukocytes	 also	 contribute	 to	 this	
proinflammatory	 process,	 but	 are	 rapidly	 replaced	 by	 recipient	 cells.152	 Also,	 during	 the	








present	 them	 on	 their	 surface	 in	 conjunction	 with	 MHC	 I	 or	 MHC	 II	 molecules.154-158	 The	
lymphatic	vessels	offer	a	convenient	exit	route	for	these	APCs,	and	direct	their	chemotaxis	with	
Figure	7	–	Antigen	presentation	occurs	directly	through	donor	APC	and	
MHC-molecules,	 semi-directly	 through	 recipient	 APC	 and	 donor	 MCH-











antigen	 and	 present	 it	 on	 recipient	 MHC	 molecules	 to	 the	 T	 cells	 (indirect	 antigen	
presentation).159	The	 subsequent	addition	of	 costimulatory	 signals,	 such	as	 the	B7	 family	of	
proteins,	allows	activation	of	the	T	cells.160	The	importance	of	these	costimulatory	signals	has	
been	 proven	 by	 the	 inhibition	 of	 acute	 and	 chronic	 rejection	 in	 blocking-	 and	 KO-
experiments.161-163	Allorecognition	has	been	detected	as	early	as	3-8	days	after	transplantation	
in	 mice	 in	 the	 form	 of	 donor-specific	 effector	 T	 cells	 in	 recipient	 secondary	 lymphoid	
tissues.132,139	
	






semi-direct	 and	 indirect	 pathways	 function	 to	 maintain	 an	 effective	 chronic	 allospecific	
adaptive	immune	response.152	Also,	host	intragraft	APCs	and	graft	VECs	direct,	facilitate	and	




cell-mediated	 cytotoxicity,	 and	 inefficient	 interaction	 with	 recipient	 T	 cells	 challenge	 the	
importance	 of	 the	 direct	 antigen	 presentation	 pathway	 in	 initiating	 a	 sufficient	 alloreactive	
response.165,166	Nevertheless,	Liu	et	al.	have	recently	established	the	importance	of	the	transfer	
of	 exosomes	 from	 a	 few	 donor-derived	 APCs	 to	 a	 several-fold	 higher	 number	 of	 recipient	
conventional	DC	in	allorecognition.166	These	findings	emphasize	the	importance	of	the	semi-





Upon	 activation	 by	 their	 cognate	 antigen,	 inflammatory	 transcription	 factors	 activate	
downstream	 cytokine	 production	 by	 T	 cells.	 The	 extent	 of	 DAMP	 release,	 cytokine	 milieu,	
degree	 of	 MHC-mismatch,	 and	 intensity	 of	 the	 innate	 reaction	 determines	 the	
subdifferentiation	of	the	T	cells.	Bolton	et	al.	demonstrated	the	important	role	of	T	lymphocytes	
in	 allograft	 rejection	using	 adoptive	 transfer	models	of	 primed	alloantigen-reactive	CD4+	or	
CD8+	T	lymphocytes	into	T	cell-depleted	athymic	allograft	recipient	rats.167	So	far,	the	important	
	 27	
roles	 of	 Th1,	 Th2,	 and	 Th17	CD4+	 helper	 T	 cell	 subclasses	 have	 been	well-characterized	 and	
established	in	the	setting	of	allograft	rejection.168		
	
The	 Th1	 and	 Th2	 response	 –	 There	 is	 clear	 evidence	 of	 the	 important	 role	 of	 Th1	 cells	 in	





and	 stimulate	 clonal	 expansion	 of	 activated	 both	 CD4+	 and	 CD8+	 T	 cells	 by	 producing	 IL-2.	














The	 Th17	 response	 –	 the	 combination	 of	 cytokines	 IL-6	 and	 TGF-β	 induces	 the	 RORgt	
transcription	factor,	which	drives	the	Th17	phenotype	in	activated	T	cells.	Interleukin	23	serves	
to	maintain	 the	 Th17	 phenotype.	 Studies	 have	 shown	 that	 especially	 IRI-induced	 release	 of	
HMBG-1	activates	innate	immune	cells	that	induce	the	Th17	response,	highlighting	the	role	of	
Th17	T	cells	in	acute	allograft	rejection.120	The	hallmark	of	the	proinflammatory	Th17	response	
is	 IL-17	secretion,	 that	can	mediate	severe	allograft	 rejection	even	 in	 the	absence	of	a	Th1-














B	 cell	 response	 –	once	 activated,	 B	 cells	 differentiate	 into	 plasma	 cells	 and	 start	 producing	
allospecific	antibodies.	Antibody-mediated	allograft	damage	occurs	to	a	large	degree	through	






of	antibody-	and	complement-mediated	rejection.	 It	 is	caused	by	pre-sensitization,	 involving	
the	 presence	 of	 preformed	 recipient	 alloreactive	 antibodies,	 most	 commonly	 anti-HLA-




















immune	 responses	 and	 allograft	 endothelial	 dysfunction	 acting	 in	 concert	 to	 initiate	 an	
aberrant	 allograft	 healing	 process.	 This	 response-to-injury	 mechanism	 involves	 impaired	
vascular	 smooth	 muscle	 cell	 proliferation	 and	 migration	 within	 the	 intima	 of	 the	 allograft	






allografts.116,118,119,191-194	 Heart	 transplant	 interstitial	 fibrosis	 involves	 the	 accumulation	 of	
Figure	8	–	Sequences	leading	to	chronic	allograft	rejection	and	vasculopathy.	The	heart	transplant	tissue	damage	during	brain	





circulating	 recipient	 progenitor	 cells,	 or	 develop	 as	 a	 result	 of	 epithelial	 to	 mesenchymal	





In	 addition	 to	 their	 proinflammatory	 qualities,	 immune	 cells	 have	 a	 considerable	 role	 in	
maintaining	tissue	homeostasis	and	inflammatory	senescence.	During	inflammatory	states,	a	
subcategory	of	regulatory	cells	function	to	limit	the	inflammatory	response,	and	in	some	cases,	
to	 extinguish	 it.	 In	 addition	 to	 distinguished	 phenotypically	 regulatory	 cells,	 some	primarily	
proinflammatory	 leukocytes	express	 regulatory	 functions	 innately.	 These	 immunoregulatory	
qualities	of	immune	cells	have	been	a	topic	of	interest	not	only	in	cancer	biology,	but	also	in	
the	 field	of	 transplant	 immunology	 recently.	 In	 the	case	of	 transplantation,	 the	presence	of	










proliferation	and	cytotoxic	 capabilities	of	a	 specific	 subset	of	NK	cells.200,201	Also,	 recently	a	
bipolar	subset	of	tumor-associated	neutrophils	has	been	identified	that	may	exhibit	either	an	
inflammatory	(N1)	or	immunosuppressive	(N2)	phenotype	context-dependently	in	tumors.	The	




Macrophages	 –	 according	 to	 current	 paradigm,	 macrophages	 polarize	 into	 two	 distinct	
phenotypes	according	to	the	activation	signals	they	receive:	the	classically	activated	(M1)	and	





further	 divided	 into	 M2a,	 M2b,	 and	 M2c	 macrophages.207	 M2a	 macrophages	 are	 mainly	



















response.207	 Also,	 IFN-g-mediated	 induction	 of	 regulatory	 macrophages	 may	 result	 in	 the	








12p70	 and	 high	 anti-inflammatory	 IL-10,	 TGF-β,	 IL-27,	 HO-1,	 galectin-1,	 NO,	 DC-SIGN,	 and	
indoleamine-2,3-dixygenase	 production	 (IDO).215,216	 Interleukin-10	 and	 TGF-β	 function	 to	
inhibit	DC	maturation	and	to	maintain	the	tolerogenic	state	of	DCs.	They	also	have	the	ability	
to	 promote	 death	 of	 effector	 inflammatory	 T	 cells	 via	 the	 Fas/FasL	 pathway	 and	 IDO	
production,	 and	 to	 stimulate	 the	 expansion	 of	 Treg	 populations.217-219	 In	 addition	 to	
CD4+CD25hiFoxp3+	Treg	cells,	tolerogenic	DCs	are	capable	of	inducing	activation	and	proliferation	
of	CD8+	Tregs,	regulatory	B	cells,	and	double-negative	T	cells.220-222	The	latter	subtype	of	Treg	cells	
produce	 IFN-g,	 which	 is	 essential	 for	 the	 immunosuppressive	 effects	 of	 tolerogenic	 DCs.220	









into	 mononuclear	 (CD11b+Ly6G-Ly6Chi)	 and	 polymorphonuclear	 (CD11b+Ly6G+Ly6Clo)	













recognition.234-236	 Different	 myeloid	 cells,	 however,	 have	 variable	 susceptibility	 to	 NK	 cell-
mediated	 cytotoxicity,	 such	 that	 for	 example	monocyte-derived	macrophages	 are	 relatively	







induce	 Treg	 activity	 via	 expression	 of	 IL-10,	 prostaglandin	 E2,	 TGF-β,	 and	 direct	 contact.241	
Mesenchymal	 stromal	 cells	 also	 play	 a	 role	 in	 maintaining	 immature	 tolerogenic	 DCs	 and	
inhibiting	 the	 production	 of	 graft-specific	 alloantibodies.242,243	 Studies	 have	 established	 the	








Regulatory	 CD4+	 T	 cells	 (Treg)	 –	 these	 cells	 present	 in	 two	 forms:	 natural	 (nTreg)	 and	
induced/adaptive	 (iTreg)	 Treg	 cells.	 Natural	 Treg	 cells	 arise	 from	 the	 thymus	 and	 function	 to	
suppress	 self-directed	 immune	 responses	 in	 the	 periphery.	 Induced	 Treg	 cells,	 on	 the	 other	
hand,	are	CD4+	T	cells	that	differentiate	into	the	regulatory	type	extrathymically.246	Both	types	
are	characterized	by	high	expression	of	transcription	factor	forkhead	box	P3	(FoxP3).	They	can	
inhibit	 effector	 cells	 of	 both	 the	 innate	 and	 adaptive	 immune	 system.	 The	 cytotoxic	 T	
lymphocyte	antigen	4	(CTLA4)	on	the	Treg	surface	binds	to	the	costimulatory	molecules	CD80/86	
on	mature	 APCs,	 decreasing	 their	 costimulatory	 actions	 and	 inducing	 IDO	 expression.247,248	
Also,	the	surface	ATP-catalyzing	CD39	of	Treg	cells	decreases	the	extracellular	ATP	availability,	
leading	to	decreased	APC	activity	and	costimulatory	drive.249	Treg	cells	also	use	their	lymphocyte	
















Regulatory	 CD8+	 T	 cells	 –	 two	 distinct	 populations	 of	 regulatory	 CD8+	 T	 cells	 have	 been	
identified:	 CD8+CD28-	 T	 cells	 and	 CD8+	 Treg	 cells.	 The	 former	 population	 are	 induced	 by	













The	 concept	 of	 gene	 therapy	 involves	 introducing	 an	 exogenous	 gene	 into	 target	 cells	 and	








modified	 viruses,	 each	with	 their	 own	 unique	 qualities	 and	 several	 serotypes.	 The	 nonviral	






Retroviruses	 are	 characterized	 by	 their	 ability	 to	 transduce	 dividing	 cells,	 justifying	 their	
frequent	 utilization	 in	 gene	 therapy	 of	 somatic	 and	 germline	 cells,	 most	 commonly	 in	 situ	
treatments.273	Their	lack	of	viral	proteins	renders	them	replication	deficient	and	reduces	their	
immunogenicity.	 Their	 poor	 ability	 to	 transduce	 non-dividing	 cells	 and	 inefficient	 in	 vivo	
transduction,	 however,	 limits	 their	 use	 for	 in	 vivo	 gene	 delivery.273,274	 Also,	 retroviruses	
integrate	 into	 the	 host	 DNA,	 which,	 on	 one	 hand,	 secures	 long-term	 efficient	 transgene	
expression,	but,	on	the	other	hand,	increases	the	risk	of	malignancy.	This	was	the	unfortunate	
case	 in	 the	 revolutionary	 first	 clinical	 gene	 therapy	 trial	 of	 children	 with	 X-linked	 severe	
combined	 immunodeficiency	 syndrome	 (X-SCID),	 in	 which	 four	 of	 the	 11	 treated	 patients	






After	 the	aforementioned	X-SCID	 incident	with	 retroviruses,	HIV-derived	 lentiviruses	 gained	
interest	 among	 scientists	 and	 clinicians.	 Although	 carrying	 the	 potential	 for	 insertional	
mutagenesis,	their	mutagenic	risk	seems	lower	than	retroviruses.279,280	Despite	being	a	subclass	
of	 retroviruses,	 lentiviruses	 are	 capable	 of	 transducing	 both	 dividing	 and	 non-dividing	
cells.274,281	This	capability	stems	largely	from	the	integrase	protein,	matrix	protein,	viral	protein	
R,	 and	 polypurine	 tract	 that	 they	 harbour.281-283	 To	 address	 the	 risk	 of	 malignancy,	 non-
integrating	lentiviruses	have	been	designed.	These	integrase-deficient	lentiviruses	have	intact	




Alzheimer’s,	 lysosomal	 storage	diseases,	 and	 spinal	 injury.284,285	 Lentiviruses	have	also	been	
used	in	gene	immunotherapy	to	induce	leukocyte-specific	transgene	expression	to	target	for	

















dividing	 and	 non-dividing	 cells.293	 Intravenous	 injection	 of	 serotype	 5	 favours	 hepatocyte	
transduction	via	coagulation	factor	X-mediated	heparan	sulfate	proteoglycan	binding.294	Also,	
serotype	 5	 tends	 to	 transduct	 Kupffer	 cells	 via	 scavenger	 receptor-A.294	 Their	 lack	 of	 host	
genome	integration	and	high	pathogenicity	renders	their	gene	expression	levels	transient	and	
their	 clinical	 use	 dangerous,	 respectively.	 In	 the	mouse,	 a	 strong	 innate	 immune	 response	
directed	at	the	capsid	proteins	initiates	shortly	after	intravenous	injection	and	peaks	at	6	hours	
after	 injection.295	 Also,	 their	 high	 immunogenicity	 limits	 their	 use	 to	mainly	 liver,	 lung,	 and	
localized	cancer	therapies.296,297	Neutralizing	antibodies	are	mainly	directed	towards	the	three	
major	 capsid	 proteins:	 the	 penton	 base,	 fiber,	 and,	 particularly,	 the	 hexon.298,299	 Also,	
adenovirus-sensitive	CD4+	T	cells	have	been	isolated	from	individuals	of	nearly	all	age	groups.300	
Modified	 replication-deficient	 adenoviruses	 have	 been	 developed,	 however,	 that	 provide	 a	








genome,	 consisting	 of	 two	 large	 open	 reading	 frames	 (ORF)	 flanked	 by	 inverted	 terminal	
repeats	(ITR).303,304	The	left	ORF	encodes	four	replication	proteins,	whereas	the	right	one	three	
viral	 structural	 proteins	 VP1-3.303-305	 The	 ITRs	 encode	 the	 elements	 required	 for	 genome	

















The	 life-cycle	and	 transduction	kinetics	of	AAVs	 include	cellular	binding,	 -entry,	 intracellular	
trafficking,	 nuclear	 entry,	 viral	 uncoating,	 and	 second-strand	 synthesis.	 Inefficient	 rAAV	
trafficking	 and	 second-strand	 synthesis	 have	 been	 identified	 as	major	 rate-limiting	 steps	 in	
rAAV	gene	expression.316,317	Although	the	precise	transduction	mechanisms	of	AAVs	has	not	
been	 elucidated	 yet,	 the	 current	 theory	 proposes	 several	 entry	 mechanisms	 ranging	 from	
micropinocytosis	and	clathrin-coated	pits	and	vesicles	to	lipid	raft-based	mechanisms.318-320	In	
addition	 to	 viral	 attachment	 receptors,	 the	 cellular	 AAV	 receptor	 mediates	 the	 entry	 of	
rAAVs.321	 Figure	11	depicts	 the	 clathrin-mediated	entry	 and	 cellular	 trafficking	of	 rAAV2.	 In	
short,	after	receptor	binding,	dynamin-mediated	clathrin-coated	pitting	occurs	and	pinches	off,	
forming	a	clathrin-coated	vesicle	holding	the	rAAV2	virus.322	The	intracellular	trafficking	of	the	
vesicle	 involves	 Rac1-	 and	 phosphatidylinositol	 3-kinase-mediated	 microtubular	 transfer	
towards	the	nucleus.318	Next,	the	intravesicular	pH	is	lowered	via	endosomal	proton	pumps,	
promoting	the	externalization	of	phospholipase	A2	and	nuclear	localization	sequence-carrying	














evokes.332	 A	 humoral	 response,	 on	 the	 other	 hand,	 is	 more	 likely,	 as	 evidenced	 by	 a	 96%	
incidence	of	AAV-specific	antibodies	in	subjects	of	a	clinical	AAV	study.333,334	These	neutralizing	
antibodies	have	been	shown	to	limit	pulmonary	and	hepatic,	but	not	muscle,	brain,	or	retina	




Clinical	 trials	 with	 AAV	 have	 been	 carried	 out	 to	 treat	 for	 example	 Parkinson’s	 disease,	
haemophilia,	rheumatoid	arthritis,	and	cystic	fibrosis.	Although	not	all	studies	were	successes,	









Several	 experimental	 animal	models	of	 cardiac	 transplantation	have	been	 carried	out	using	
both	recombinant	adenovirus	and	AAV	vectors.	Therapies	including	HO-1,	heat	shock	proteins,	
CTLA4-Ig,	 and	 CD40-Ig,	 along	 with	 IL-18-,	 RANTES-,	 and	 CCL2-antagonists	 have	 shown	




















gene	 in	 mice	 is	 lethal	 and	 results	 in	 cardiovascular	 abnormalities.354	 Vascular	 endothelial	
growth	factor	A	has	potent	pro-angiogenic	and	vasodilatory	effects	and	binds	to	VEGFR-1,	-2,	
NRP1,	 and	 -2.355	 Its	 angiogenic,	 mitogenic,	 and	 permeability	 effects	 are	 mainly	 mediated	
through	VEGFR-2,	causing	EC	proliferation,	sprouting,	and	tube	formation.356-358	In	the	setting	
of	 heart	 transplantation,	 VEGF-A	 induces	 expression	 of	 adhesion	 proteins	 and	
chemoattractants	from	VECs,	and	plays	a	significant	role	in	both	acute	and	chronic	rejection	of	







Vascular	endothelial	growth	 factor	B	 is	expressed	 in	 the	majority	of	 tissues,	particularly	 the	
heart.360,361	Alternative	splicing	of	the	VEGF-B	gene	yields	two	isoforms:	VEGF-B167	and	VEGF-









the	 trafficking	 of	 free	 fatty	 acids	 by	 VECs	 and	 the	 induction	 of	 fatty-acid	 oxidation	 on	 a	
transcriptional	 level.372-374	 Others	 have	 found	 a	 protective	 role	 of	 VEGF-B	 in	 ischemic	





Vascular	 endothelial	 growth	 factor	 C	 is	 produced	 as	 a	 precursor	 protein,	 but	 undergoes	
proteolytic	cleavage	to	achieve	its	biologically	active	form.378	It	binds	to	VEGFR-2	and	-3,	and	is	
produced	in	the	lung,	heart,	liver,	and	kidney	in	adults.378,379	Dendritic	cells,	macrophages,	and	





excessive	 lymphangiogenesis	 that	 results	after	VEGF-C	overexpression.367,383	 It	 is	 involved	 in	
several	 inflammatory	 conditions,	 including	 bacterial	 infections,	 organ	 transplantation,	 and	
rheumathoid	arthritis,	and	has	direct	effects	on	lymphatic	vessels	and	inflammatory	cells	by	for	




























Oxygen	 (O2)	 is	one	of	 the	 fundamental	 requirements	 for	human	 life.	On	a	 cellular	 level,	O2	
enables	ATP	production	via	oxidative	phosphorylation	by	serving	as	the	final	electron	acceptor	
in	 the	 mitochondrial	 electron	 transport	 chain.	 Cells,	 however,	 have	 several	 adaptive	





Hypoxia-inducible	 factor	 is	 a	 transcriptional	 factor	 consisting	 of	 an	 oxygen-labile	 α-subunit	










α	 to	 escape	 hydroxylation	 and	 to	 dimerize	 with	 HIF-β.399,400	 Similarly,	 ROS,	 NO,	 and	
intermediates	of	the	tricarboxylic	acid	cycle	have	been	shown	to	inhibit	the	activity	of	PHDs,	
with	 ROS	 also	 suppressing	 FIH,	 resulting	 in	 HIF-α	 stabilization	 (Figure	 13).401-403	 The	
mitochondrial	 deacetylase	 sirtuin-3,	 on	 the	 other	 hand,	 blocks	 the	 formation	 of	 ROS	 by	
Figure	 14	 –	 During	 hypoxia,	 HIF-α	 dimerizes	 with	 HIF-β	 and	 proceeds	 to	 form	 a	 transcriptional	 complex	with	 PKM2	 and	
P300/CBP.	PKM2,	pyruvate	kinase	isoform	M2;	CBP,	creb-binding	protein;	HIF,	hypoxia-inducible	factor.		


















Metabolism	 – To	 allow	 cells	 to	 adapt	 to	 hypoxia,	 HIFs	 promote	 anaerobic	 glycolysis	 by	
transcriptional	regulation	of	key	metabolic	factors.	First,	the	expression	of	glucose	transporters	
GLUT1	and	GLUT3,	along	with	glycolytic	enzymes	hexokinases	1	and	2	and	phosphoglycerate	
kinase	 1	 are	 increased.407-409	 Next,	 the	 expression	 of	 lactate	 dehydrogenase	 A	 (LDHA)	 is	
stimulated,	enhancing	the	regeneration	of	NAD+	for	use	 in	glycolysis.410	This,	along	with	the	
induction	of	pyruvate	dehydrogenase	kinase-1	and	-3	(PDK1),	shunts	pyruvate	away	from	the	
mitochondria,	 reducing	 oxidative	 phosphorylation	 and	 cellular	 oxygen	 consumption.411,412	
Furthermore,	studies	have	demonstrated	that	VHL	KO	of	renal	carcinoma	cells	induces	MXI-1,	
which	causes	suppression	of	PGC-1α,	a	critical	mediator	of	mitochondrial	biogenesis.413	Also,	




edema	 and	 increased	 local	 oxygen-consumption,	 activating	 HIF	 in	 both	 resident	 cells	 and	
infiltrating	leukocytes.415	As	opposed	to	parenchymal	cells,	HIF	may	be	stabilized	in	an	oxygen-
independent	manner	in	immune	cells.	Among	innate	leukocytes,	bacteria	and	PRR	ligation	can	
induce	HIF-1α	 oxygen-independently.416,417	 Also,	 TNF-α	 and	 ROS	may	 stabilize	 HIF-1α	 in	 an	
oxygen-independent	 fashion.418,419	 In	 fact,	myeloid	 cell-specific	 deletion	 of	 HIF-1α	 causes	 a	
profound	decrease	in	the	anti-bacterial	capabilities	of	neutrophils	and	macrophages,	further	
suggesting	 an	 important	 role	 of	 HIF	 for	 successful	 inflammatory	 responses.420	 In	 general,	
activation	of	HIF,	particularly	HIF-1α,	in	inflammatory	cells	induces	a	metabolic	reprogramming	
to	increase	the	production	of	ATP,	which	enables	active	aggregation,	invasion,	and	motility	of	
leukocytes,	 especially	 macrophages.420	 In	 macrophages	 and	 DCs,	 proinflammatory	 stimuli	
stabilize	HIF-1α,	 leading	to	enhanced	glycolysis	and	reduced	oxidative	phosphorylation	in	an	
iNOS	 and	 NO-dependent	 manner,	 much	 like	 the	 Warburg	 effect	 in	 tumor	 cells.421	 These	
metabolic	changes	ensure	sufficient	energy	production	for	leukocytes	to	carry	out	their	effector	





κB,	 increases	 the	 production	 of	 antimicrobial	 granule	 contents	 (cathelicidin,	 cathepsin	 G,	
elastase),	and	enhances	epithelial	binding	via	induction	of	β2	integrin	expression.416,423,424		
	
In	 macrophages,	 NF-κB	 and	 TNF-α expression	 stabilize	 HIF-1α,	 whereas	 IL-4	 stabilizes	 HIF-
2α.418,425,426	 Hypoxia-inducible	 factor-1α	 mediates	 the	 differentiation	 of	 monocytes	 to	
macrophages,	enhances	microbial	phagocytosis,	and	stimulates	the	expression	of	TNF-α,	iNOS,	
and,	 consequently,	 NO.416	 Hypoxia-inducible	 factor-2α	 also	 stimulates	 the	 production	 of	
cytokines	TNF-α,	IFN-g,	IL-1β,	and	IL-12,	but	does	not	affect	NO	expression	in	macrophages.427	
Overall,	hypoxia	enhances	the	expression	of	a	plethora	of	inflammatory	receptors,	cytokines	
and	 angiogenic	 factors	 by	 macrophages,	 including	 IL-1α,	 IL-1β,	 IL-6,	 IL-8,	 IL-12,	 VEGF,	
angiopoietins,	and	CXCR4,	as	well	the	surface	expression	of	TLRs	2,	4,	6,	and	9.415-417,428-430	On	
the	other	hand,	studies	have	highlighted	an	 important	 role	of	HIF-2α	 in	mediating	 the	anti-
inflammatory	and	pro-tumor	effects	of	tumor-associated	macrophages	(TAM).427	Also,	the	M2	
polarization	 of	 macrophages	 seems	 to	 be	 HIF-2α-dependent	 and	 arginase-driven	 and	 is	
characterized	 by	 moderate	 glycolytic-	 but	 high	 oxidative	 activity,	 particularly	 fatty	 acid	








acquire	 profound	 immunosuppressive	 abilities	 via	 HIF-1α-regulated	 iNOS	 and	 Arg1	
expression.432	 In	 fact,	 in	 cancer	 tissue,	 HIF-1α	 expression	 is	 associated	 with	 a	 poor	 clinical	




triggering	 receptor	 expressed	 on	 myeloid	 cells	 (TREM-1),	 leading	 to	 DC	 maturation	 and	




have	 described	 decreased	 DC	 maturation	 and	 antigen	 presenting	 capabilities	 in	 a	 hypoxic	





both	 HIF-1α	 and	 -2α	 in	 an	mTOR-dependent	manner	 after	 TCR	 ligation.441-443	 Interleukin-2	
induces	 HIF-1α	 stabilization,	 whereas	 IL-4	 induces	 HIF-2α	 stabilization	 in	 CD8+	 T	 cells.426,443	
Hypoxia-inducible	 factor-2α	 plays	 a	 pivotal	 role	 in	 the	 ability	 of	 CD8+	 T	 cells	 to	mount	 and	
maintain	 an	 effective	 anti-microbial	 and	 oncolytic	 response.443	 Also,	 HIF	 promotes	 Th17	
differentiation	by	enhancing	glycolysis	and	transactivating	RORgt.444	This	is	evidenced	by	the	
finding	 that	HIF-1α-/-	 T	 cells	 fail	 to	 inhabit	Th17	characteristics,	even	after	 culturing	 in	Th17-
promoting	conditions.444	Furthermore,	HIF-1α	inhibits	the	development	of	Treg	cells	by	direct	
marking	of	Foxp3	 for	ubiquitin-mediated	degradation,	but,	on	 the	other	hand,	 seems	 to	be	
required	for	effective	Treg	effector	functions	during	certain	conditions.444	Moreover,	in	a	murine	
model	 of	 colitis,	 HIF-1α	 was	 indispensable	 for	 Treg	 differentiation.445	 Similarly,	 HIF-1α	 may	








prime	 example	 of	 this	 is	 cancer,	 which	 uses	 angiogenesis	 and	 lymphangiogenesis	 to	 both	
maintain	 the	 supply	of	oxygen	and	nutrients,	and	 to	establish	metastases.447	As	an	oxygen-
sensitive	transcription	factor,	HIF	plays	an	 important	role	 in	angiogenesis.448	The	profoundly	




VEGF-A,	 PlGF,	 Ang1	 and	 -2,	 PDGF-B,	 and	 their	 corresponding	 receptors.450-454	 Also,	 HIF	
stimulates	 the	 expression	of	 a	 plethora	of	matrix	 remodelling	 agents	 that	 create	 a	 suitable	
environment	 for	 VEC	 proliferation,	 migration,	 and	 tube	 arrangement,	 including	 matrix	
metalloproteinases,	 plasminogen	 activator	 receptors	 and	 inhibitors,	 and	 procollagen	 prolyl	
hydroxylase.448	Macrophages	are	also	a	rich	source	of	VEGF,	which	is	stimulated	by	HIF-1α,	but	






detected	 in	biopsies	 from	human	kidney	allografts.458	 Inhibiting	PHDs	 in	 rat	kidney	allograft	
donors	activated	HIF	and	prevented	graft	injury	and	prolonged	allograft	survival.459	In	contrast,	
Keränen	 et	 al.	 demonstrated	 that	 recipient,	 but	 not	 donor,	 treatment	with	 a	 PHD-inhibitor	
attenuated	allograft	acute	rejection	and	improved	long-term	survival.460	Furthermore,	cardiac	
allograft	 ischemia	 and	 acute	 and	 chronic	 rejection	 increases	 intracardiac	 HIF	 activity.461,462	
Schneider	 et	 al.	 demonstrated	 ischemia-resistance	 in	 PHD-/-	 hepatic	 allografts	 in	 mice.463	

























Permission	 for	 animal	 experimentation	 was	 obtained	 from	 the	 State	 Provincial	 Office	 of	
Southern	Finland.	The	animals	received	care	in	compliance	with	the	“Guide	for	the	Care	and	
Use	of	Laboratory	Animals”	prepared	by	the	National	Academy	of	Sciences	and	published	by	
the	 National	 Academies	 Press	 (ISBN	 0-309-15400-6,	 revised	 2011).	 All	 gene	 therapy	





All	 procedures	 were	 performed	 with	 the	 animals	 under	 general	 anesthesia	 with	 inhalable	
Isoflurane.	All	animals	received	buprenorphine	(Temgesic)	as	perioperative	analgesia.	
	
Heart	procurement:	 First,	 the	donor	heart	was	perfused	with	 ice-cold	heparin-PBS	 solution.	
Next,	 the	caval	and	pulmonary	veins	were	 ligated	en	bloc	by	posterior	 ligature	and	excised.	
Finally,	the	aorta	and	pulmonary	artery	were	excised	and	the	heart	removed	from	the	thoracic	
cavity	 for	 ex	 vivo	 preservation	 in	 ice-cold	 +4°C	 heparinized	 PBS	 during	 preparation	 of	 the	
recipient.	
	
Preparation	 of	 the	 recipient:	 Laparotomy	 was	 performed	 along	 the	 linea	 alba	 to	 minimize	
intraoperative	bleeding.	The	abdominal	descending	aorta	and	inferior	vena	cava	were	prepared	













Rat	 Dark	Agouti	 Dark	Agouti	 1	
No	IRI:	0	
IRI:	2	or	4	
Mouse	 Balb/C	 Balb/C	 1	
Allogeneic	 Rat	 Dark	Agouti	 Wistar	Furth	 1	


































aorta	 and	 pulmonary	 artery	 were	 clamped	 after	







Recombinant	 vector	 production,	 cell-lines	 and	







associated	 virus;	 ITR,	 inverted	 terminal	 repeat;	
CMV,	cytomegalovirus,	WPRE,	woodchuck	hepatitis	
virus	 post-transcriptional	 response	 element;	 pA,	
poly-Adeno;	 Amp,	 ampicillin-resistance	 gene;	 ori,	
origin	of	replication.	
	 50	
recombinant	 rAAV	vector	plasmid,	 the	AAV	packaging	plasmid	pAAV/Ad-rep	 (ACG),	 and	 the	
adenovirus	helper	plasmid	pBS-E2A-VA-E4	(Figure	18).	After	48	hours,	we	released	the	rAAVs	




Immunosuppression:	 Syngeneic	 transplant	 recipients	 received	 no	 immunosuppression.	 To	
inhibit	 acute	 allograft	 rejection	 and	 to	 allow	moderate	 chronic	 inflammation,	 recipients	 of	






using	 transgenic	 rat	 strains,	whereas	 the	effects	of	 short-term	VEGF-B	overexpression	were	
investigated	 using	 local	 Adenoviral	 delivery	 of	 VEGF-B	 to	 allografts	 (Figure	 19).	 In	 both	
experiments,	 cold	 preservation	 and	 warm	 ischemia	 times	 were	 2	 hours	 and	 1	 hour,	











Effect	of	 ischemia	and	 reperfusion	on	heart	VEGF-B	mRNA	expression:	We	 subjected	hearts	
from	wild-type	DA	 rats	 to	 2h	ex	 vivo	 cold	 ischemia	with	 or	without	 an	 additional	 1h	warm	




Effect	of	 chronic	VEGF-B	overexpression	on	heart	 transplant	 IRI	 (Figure	19):	We	performed	
intra-abdominal	heterotopic	heart	 transplantations	 from	specific	pathogen-free	male	Wistar	
















respectively,	with	C57Bl/6	mice	 carrying	 the	myeloid-lineage-specific	 lysozyme	M	promoter	
(LysMCre)	 allele,	 deleting	 the	 floxed	 gene	 specifically	 in	 the	 myeloid-lineage.	 The	 result	 is	
homozygous	deficiency	of	HIF-1α	(constant	HIF-1α	inactivation)	or	VHL	(constant	activation	of	







was	 investigated	 in	 vitro.	 Next,	 the	 transgenic	 effect	 was	 researched	 in	 vivo	 by	 using	 the	
transgenic	mice	as	recipients	for	fully	MHC-mismatched	heart	allografts	in	IRI,	acute	rejection,	
and	survival	models.	Finally,	the	effect	of	myeloid-derived	cell-specific	HIF	activation	(VHL	KO)	





via	 cervical	 dislocation,	 the	 peritoneal	 cavity	 was	 infused	 with	 ice-cold	 PBS	 and	 gently	
massaged.	 Next,	 the	 peritoneal	 lavage	 was	 collected	 through	 a	 mid-line	 laparotomy,	
centrifuged	 for	 10	minutes,	 washed	 with	 PBS,	 rid	 of	 erythrocytes,	 and	 the	 final	 cell	 pellet	
collected	 into	 RPMI	 comprising	 10%	 heat-inactivated	 fetal	 bovine	 serum,	 penicillin	 100	














Microbeta	 liquid	 scintillation	 counter	 (Wallac,	 Turku,	 Finland)	 using	 OptiScint	 HiSafe	
scintillation	 fluid	 (PerkinElmer,	 Waltham,	 MA).	 Background	 from	 non-stimulated	 wells	 was	



















































Cryostat	 sections	were	 stained	 using	 the	 peroxidase	 ABC	method	 (Vectastain	 Elite	 ABC	 Kit,	
Vector	 Laboratories,	 Inc.,	 Burlingame,	 CA)	 and	 the	 reaction	 revealed	 by	 3-amino-9-





Survival	 data	 is	 presented	 in	 Kaplan-Meier	 plots.	 P-values	 for	 the	 survival	 analyses	 were	
obtained	with	the	log-rank	test,	and	hazard	ratios	(HR)	with	confidence	intervals	(CI)	with	the	
Cox	 regression	 test.	 Linear	data	was	analyzed	with	 the	parametric	 Student’s	 t-test	 for	 two-
group	comparisons	and	One-way	ANOVA	for	comparison	of	multiple	groups.	Non-linear	data	
was	 analyzed	with	 the	 non-parametric	Mann-Whitney	 test	 for	 two-group	 comparisons	 and	



















































copies	at	one	month	after	 transplantation,	with	a	 trend	towards	higher	 intragraft	 luciferase	
protein	 activity	 as	 well	 (Figure	 23).	 Two	 hours	 of	 cold	 ischemia	 reduced	 the	 numbers	 of	



















In	 syngrafts,	 the	 number	 of	 intragraft	 ED-1+	 macrophages,	
MPO+	 neutrophils,	OX-62+	DCs,	 and	CD4+	 T	 cells	was	 similar	
between	 the	 serotype	groups	 compared	 to	 control	 samples.	
The	number	of	CD8+	cytotoxic	T	cells,	however,	was	increased	
in	 AAV9-Luc-perfused	 syngrafts	 at	 6	 months	 after	
transplantation.	 In	 allografts,	 the	 number	 of	 CD11b+	
macrophages	were	increased	in	AAV9-Luc	perfused	hearts	at	4	
weeks	after	transplantation.	The	extent	of	fibrosis	and	CAV	was	
unchanged	 in	 AAV-perfused	 hearts	 compared	 to	 control	
samples	among	both	syngrafts	and	allografts.		
	
Donor	 intravenous	 delivery	 of	 AAV9	 results	 in	 local	 heart	
transplant	transgene	expression	
	
To	 determine	 the	 effect	 of	 route	 of	 administration	 on	 the	









transplantation	 after	 6	 weeks	 (top	
panel),	 or	 into	 the	 coronary	 circulation	
ex	 vivo	 before	 implantation	 into	 the	
recipient	 (lower	 panel)	 and	 examined	
the	 luciferase	 signal	 with	 non-invasive	
bioluminescent	 imaging	 for	 4-8	 weeks.	

























Hearts	 preserved	 in	 cold	 solution	 for	 2	 hours	 witnessed	 a	 significant	 increase	 in	 qRT-PCR-
measured	VEGF-B	mRNA	expression,	which	remained	high	at	6	hours	after	transplantation	into	
recipients	(Figure	26).	 














rats	 were	 exposed	 to	 ex	 vivo	 2-hour	
cold	 preservation	with	 or	 without	 1-
hour	warm	 ischemia	 (n	 =	 5	 /	 group).	
Native	hearts	without	ischemia	served	
as	controls.	(B)	DA	donor	hearts	were	
subjected	 to	 ex	 vivo	 2-hour	 cold	
preservation	 and	 transplanted	 into	
WF	 recipients.	 Transplants	 were	
removed	 and	 analyzed	 for	 VEGF-B	
mRNA	 expression	 at	 6	 hours	 after	
reperfusion.	 Heart	 transplants	
without	2-hour	preservation	served	as	
controls.	 Results	 are	 normalized	 to	
18S	 rRNA.	 *p<0.05.	VEGF-B,	 vascular	
endothelial	growth	factor	B;	h,	hour.	
Figure	27	–	Cardiomyocyte-specific	transgenic	human	VEGF-B	(hVEGF-B)-overexpressing	hearts	were	subjected	to	2-hour	cold	
and	 1-hour	warm	 preservation	 and	 transplanted	 into	 recipient	 rats	 in	 a	 minor	 MHC-mismatch	model	 (n	 =	 6/group).	 (A)	



















Short-term	 AAV-mediated	 cardiac	 allograft-specific	 hVEGF-B	 overexpression	 causes	
macrophage	influx	but	fails	to	induce	morphologic	changes	in	the	heart	transplant	
	




































HIF-1α	 and	 -2α	 stabilization	 in	 myeloid-derived	 cells	 induces	 an	 immunosuppressive	
phenotype	in	vitro	
	




Myeloid-derived	 cells	 from	 mVHL-/-	 mice	 had	 an	 increased	 expression	 of	 HIF-1α	 and	 anti-






























Gene	 Relative	mRNA	expression	 ±	SEM	 p-value	
Arg1	 2.1	 0.7	 0.506	
IL-33	 1.8	 0.9	 0.190	
STAT6	 1.6	 0.4	 0.169	
IL-10	 1.5	 0.2	 0.115	
CXCR2	 1.4	 0.4	 0.506	
GM-CSF	 1.4	 0.7	 0.875	
IL-2	 1.4	 0.3	 0.294	
G-CSF	 1.3	 0.7	 0.392	
HO-1	 1.2	 0.2	 0.392	
S100A9	 1.2	 0.2	 0.428	
MIP-2α	(CXCL2)	 1.0	 0.5	 0.825	
IL-12p35	 1.0	 0.1	 0.970	
RANTES	(CCL5)	 1.0	 0.3	 0.910	
STAT3	 0.9	 0.1	 0.792	
IL-6	 0.9	 0.3	 0.975	
iNOS	 0.9	 0.1	 0.294	
HIF-2α	 0.9	 0.0	 0.031	
IDO1	 0.8	 0.1	 0.384	
HIF-1α	 0.8	 0.1	 0.208	
MCP-1	(CCL2)	 0.8	 0.3	 0.428	
CD83	 0.8	 0.1	 0.975	
FOXp3	 0.7	 0.1	 0.925	
MIP-1α	(CCL3)	 0.6	 0.2	 0.270	
IP-10	(CXCL10)	 0.6	 0.1	 0.681	
IL-1β	 0.6	 0.1	 0.265	
CD80	 0.5	 0.1	 0.057	
GROα	(CXCL1)	 0.5	 0.2	 0.728	
TNF-α	 0.4	 0.0	 0.034	
















recipients	 did	 not	 receive	 any	 immunosuppression,	 allowing	 the	 development	 of	 acute	
rejection	before	removal	at	5	days	after	transplantation.	
Gene	 Relative	mRNA	expression	 ±	SEM	 p-value	
MIP-1α	(CCL3)	 2.3	 1.8	 0.494	
IL-2	 2.3	 1.2	 0.445	
RANTES	(CCL5)	 2.2	 0.4	 0.024	
STAT6	 2.2	 1.3	 0.612	
VEGF-A	 1.9	 0.2	 0.023	
IL-1β	 1.9	 0.9	 0.622	
MCP-1	(CCL2)	 1.5	 0.6	 0.335	
iNOS	 1.4	 0.2	 0.029	
IL-33	 1.4	 0.9	 0.866	
G-CSF	 1.4	 0.8	 0.933	
TNF-α	 1.4	 0.3	 0.154	
CD80	 1.4	 0.7	 0.616	
IL-10	 1.3	 0.5	 0.892	
GM-CSF	 1.2	 0.7	 0.933	
CD83	 1.1	 0.6	 0.437	
S100A9	 1.1	 0.4	 0.933	
CXCR2	 1.1	 0.5	 0.933	
HIF-2α	 1.1	 0.1	 0.213	
IL-12p35	 1.1	 0.2	 0.820	
HIF-1α	 1.0	 0.1	 0.892	
STAT3	 0.9	 0.1	 0.385	
MIP-2α	(CXCL2)	 0.8	 0.4	 0.933	
IP-10	(CXCL10)	 0.8	 0.3	 0.616	
FOXp3	 0.8	 0.1	 0.820	
IDO1	 0.8	 0.1	 0.250	
IL-6	 0.5	 0.2	 0.205	
Arg1	 0.4	 0.1	 0.045	
HO-1	 0.4	 0.0	 0.018	
GROα	(CXCL1)	 0.3	 0.1	 0.612	
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The	number	of	allograft-infiltrating	CD11b+	macrophages,	CD11c+	DC,	and	CD4+	and	CD8+	T	
cells,	 but	 not	MPO+	 neutrophils,	 was	 reduced	 in	mVHL-/-	 recipients	 compared	 to	 allografts	
transplanted	 into	 littermate	 recipients	 (p<0.05;	 Figure	 31).	 These	 allografts	 also	 showed	 a	
significantly	reduced	mRNA	expression	of	TNF-α,	 IFN-γ,	 IP-10	(CXCL10),	RANTES	(CCL5),	 IL-4,	






Gene	 Relative	mRNA	expression	 ±	SEM	 p-value	
HIF-2α	 1.71	 0.20	 0.053	
STAT3	 1.23	 0.35	 0.443	
TGF-β	 1.05	 0.34	 0.878	
S1009A	 1.03	 0.73	 0.960	
VEGF-A	 0.87	 0.35	 0.712	
CD80	 0.73	 0.24	 0.369	
THBS5	 0.68	 0.19	 0.215	
HIF-1α	 0.63	 0.12	 0.321	
CD83 0.59	 0.16	 0.167	
IL-1β	 0.57	 0.41	 0.358	
IL-17	 0.54	 0.53	 0.768	
Arg1	 0.39	 0.19	 0.135	
IL-6	 0.37	 0.15	 0.086	
IL-10	 0.32	 0.13	 0.142	
CD86	 0.28	 0.07	 0.012	
FOXP3	 0.17	 0.06	 0.014	
TNF-α	 0.17	 0.06	 0.000	
iNOS	 0.16	 0.08	 0.015	
IL-4	 0.13	 0.13	 0.026	
GM-CSF	 0.12	 0.03	 0.042	
RANTES	(CCL5)	 0.11	 0.03	 0.001	
IFN-γ	 0.04	 0.01	 0.017	
IP-10	(CXCL10)	 0.04	 0.02	 0.001	
IDO	 0.02	 0.01	 0.001	






Heart	 allografts	 transplanted	 into	mHIF-1α-/-	 recipients	 experienced	 a	 similar	 acute	 cellular	
immune	response	as	allografts	transplanted	into	littermate	mice	(Figure	31).	These	hearts	also	






To	 investigate	the	 long-term	 implications	of	 the	diminished	acute	rejection	we	performed	a	
survival	model.	Heart	allografts	were	transplanted	into	non-immunosuppressed	major	MHC-
mismatched	 littermate,	 mVHL-/-,	 or	 mHIF-1α-/-	 C57/Bl	 mice	 and	 followed-up	 with	 daily	
abdominal	palpation.	The	end-point	was	lack	of	palpable	heart	allograft	activity.	
	
The	 median	 survival	 of	 allografts	 transplanted	 into	 mVHL-/-	 recipients	 was	 significantly	
prolonged	to	20±4	days	(p<0.05;	Figure	32),	with	a	significantly	higher	cardiac	allograft	Arg1	
expression	compared	to	 littermate	controls	at	 the	moment	of	 failure	 (p<0.05;	Table	9).	The	























Gene	 Relative	mRNA	expression	 ±	SEM	 p-value	
Arg1	 2.2	 0.6	 0.012	
IL-10	 1.8	 0.8	 0.194	
MIP-1α	(CCL3)	 1.4	 0.6	 0.279	
RANTES	(CCL5)	 2.3	 1.7	 0.279	
HO-1	 1.7	 0.4	 0.133	
IFN-γ	 1.7	 0.7	 0.376	
IL-6	 1.5	 0.6	 0.279	
IL-33	 1.6	 1.1	 0.376	
iNOS	 2.5	 1.0	 0.085	
VEGF-A	 1.6	 0.6	 0.279	






Heart	 transplant	 gene	 therapy	 could	 provide	 a	 safe	 method	 for	 applying	 local	 therapeutic	
effects	to	the	allograft	without	the	dangerous	systemic	side-effects	of	the	current	multi-drug	










AAV	 serotypes	 6,	 8,	 and	 9	 have	 been	 established	 as	 the	most	 cardiotropic	 serotypes	 after	











contrary	 to	 AAV8	 and	 AAV9,	 is	 equipped	 with	 the	 extracellular	 heparan	 sulfate	 receptor,	
facilitating	 its	attachment	to	the	extracellular	matrix	and	granting	 it	a	short	blood-clearance	
time.308,468-470	Moreover,	 the	 slow	blood-clearance	of	AAV9	after	 systemic	delivery	 suggests	
that	it	requires	a	prolonged	time	to	cross	the	endothelial	layer	for	cardiac	transduction.469	In	
vivo	IVIS	imaging	of	laparotomized	recipient	rats	of	AAV9-perfused	heart	transplants	confirmed	
the	 escape	 of	 AAV9	 into	 the	 abdominal	 cavity	 of	 the	 recipients.	 Therefore,	 the	 lower	
adhesiveness	and	slow	transendothelial	access	of	AAV8	and	AAV9	may	explain	their	abdominal	







recipients.	 The	 latter	 effect	may	 also	 cause	 problems	 for	 harvesting	 and	 transplantation	 of	
other	organs,	due	to	the	versatile	context-	and	tissue-dependent	effects	of	therapeutic	genes.	
Ex	vivo	heart	transplant	perfusion,	however,	would	be	clinically	feasible,	and	could	minimize	





Ignoring	 localization,	 we	 observed	 efficient	 transgene	 expression	 at	 4	 weeks	 after	
transplantation	 with	 all	 AAV	 serotypes	 in	 both	 the	 syngeneic	 and	 allogeneic	 models.	 The	




Clinical	 translation:	 these	 vector	 kinetics	 could	 be	 suitable	 for	 clinical	 treatment	 of	 chronic	
allograft	 rejection	 or	 diagnosis	 of	 acute	 rejection	 episodes	 using	 reporter	 genes.	 Potential	
therapeutic	 proteins	 could	 include	 both	 anti-inflammatory	 and	 anti-proliferative	
factors.117,351,472	Although	AAV2	and	AAV9	show	some	transgene	activity	on	the	second	post-
operative	 day,	 these	 low	early	 transgene	 kinetics	would	most	 likely	 not	 be	 suitable	 for	 the	





Heart	 transplant	 intracoronary	 delivery	 of	 AAV8	 and	 AAV9	 induced	 a	 CD8+	 T	 cell	 response	
measured	at	6	months	after	transplantation	of	syngeneic	hearts.	This	could	partly	explain	the	
low	 transplant-specific	 transduction	 efficiency	 of	 AAV8	 and	 AAV9.	 A	 vector-directed	
inflammation	 and	 immunogenicity-mediated	 decrease	 in	 transduction	 efficiency,	 however,	
would	 be	 expected	 to	 occur	 homogenously	 in	 the	 recipient,	 and	 not	 only	 in	 the	 heart	
transplant.	 The	 recipients	 of	 AAV-perfused	 allografts,	 on	 the	 other	 hand,	 were	
immunosuppressed	with	daily	doses	of	cyclosporine.	This	may	have	blunted	the	T	cell	response	
observed	in	syngeneic	grafts.	Adeno-associated	virus	serotype	9-perfused	allografts,	however,	
experienced	 an	 ED-1+	 macrophage	 response	 4	 weeks	 following	 transplantation.	 Heart	


















AAV9	 have	 higher	 immunogenicity	 than	 AAV2	 in	 the	 rat,	 which	must	 be	 considered	 when	
choosing	a	vector	for	clinical	trials.	A	large	proportion	of	the	population	are	infected	with	latent	
AAV	and	the	majority	possess	viral	capsid	protein-targeted	neutralizing	antibodies.333,477	This	is	
a	 major	 barrier	 limiting	 recipient	 transgene	 expression	 in	 clinical	 trials,	 and	 should	 be	
considered	when	applying	gene	therapy	to	clinical	heart	transplantation.	Some	studies	have	






Our	 results	 highlight	 the	 importance	 of	 route	 of	 administration	 on	 heart	 transplant	 vector	

















Vascular	 endothelial	 growth	 factor	 B	 overexpression	 induces	 cardiac	 hypertrophy.375,376	
Moreover,	 it	 reduces	 ischemic	 CMC	 injury	 in	 a	myocardial	 infarction	model	 and	 decreases	
apoptosis	via	BH3	inhibition	both	in	vitro	and	in	vivo.365,369,375,376,480	Our	experiments,	however,	
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Short-term	 AAV-mediated	 heart	 transplant	 VEGF-B	 overexpression	 failed	 to	 reproduce	 the	
cardiac	metabolic	and	morphologic	effects	of	long-term	transgenic	VEGF-B	overexpression	and	
did	not	affect	the	post-transplant	recipient	cardiac-specific	TnT	(cTnT)	release.	This	implies	that	





oxygen-induced	 vessel	 regression	 model	 of	 mouse	 corneal	 pockets.368,371	 In	 myocardial	
infarction	 models,	 VEGF-B	 treatment	 expands	 the	 coronary	 vasculature	 and	 epicardial	
arterialization.370,375,376	Vascular	endothelial	growth	factor	B	also	functions	as	a	survival	factor	
for	 VECs,	 pericytes,	 and	 SMCs	 in	 vitro.368,371	 In	 contrast,	 we	 observed	 impaired	myocardial	
perfusion	of	long-term	VEGF-B-overexpressing	hearts	after	transplantation	into	recipients.	The	
capillary	 density	 was	 similar	 to	 control	 hearts,	 suggesting	 CMC	 hypertrophy	 as	 a	 probable	
cause.	
	
Heart	 transplant	 AAV-mediated	VEGF-B	 overexpression	 caused	 an	 increased	 influx	 of	 ED-1+	






This	 study	 provides	 preliminary	 insight	 into	 the	 role	 of	 VEGF-B	 in	 heart	 transplant	 IRI.	 The	
findings	are	scarce,	but	may	suggest	a	role	for	VEGF-B	in	the	maintenance	of	CMC	oxidative	
metabolism.	Although	the	effects	of	heart	transplant	VEGF-B	overexpression	were	negative	in	
terms	 of	 post-operative	myocardial	 damage	 and	 inflammation	 in	 this	 study,	 the	 long-term	
implications	 of	 VEGF-B	 in	 heart	 transplants	 remains	 unknown	 and	 warrants	 further	
investigation.	 In	 the	 current	 study,	 however,	 donor	 rats	 were	 healthy	 and	 the	 response	
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variables	 were	 limited	 to	 myocardial	 damage	 and	 inflammation,	 ignoring	 the	 potential	
beneficial	 effects	 VEGF-B	 could	 have	 on	 myocardial	 energy	 expenditure	 and	 contractile	















after	transplantation,	with	 increased	regulatory	 IL-10	and	Arg1	and	decreased	 inflammatory	
TNF-α	 and	 VEGF-A	 expression	 at	 6h	 post-reperfusion.	 Arginase-1,	 IL-10	 and	 iNOS	 are	
characteristic	for	the	immunosuppressive	qualities	of	MDSC,	M2	macrophages,	and	regulatory	
macrophages	 and	 neutrophils.432,483	 As	 such,	 due	 to	 the	 whole-tissue	 nature	 of	 the	mRNA	





experienced	 a	 profoundly	 diminished	 adaptive	 immune	 response	 and	 acute	 rejection,	 as	
measured	by	the	decreased	influx	of	innate	immune	cells	and	T	cells,	and	reduced	expression	
of	Th1,	Th2,	and	Th17	effector	cytokines	TNF-α,	IFN-g,	IL-4,	and	IL-17.	In	vitro	experiments	further	
revealed	 that	 VHL-/-	 myeloid-derived	 cells	 were	 capable	 of	 dose-dependently	 reducing	
CD3/CD28-stimulated	antigen-nonspecific	splenocyte	proliferation.	Collectively,	these	results	
imply	 that	 the	 early	 allograft-infiltrating	 VHL-/-	 myeloid-derived	 cells	 may	 actively	 suppress	
activated	 adaptive	 immune	 cells,	 possibly	 through	 direct	 cell	 contact	 or	 ROS,	 or	 anti-
inflammatory	 Arg1,	 IL-10,	 and	 iNOS	 expression.	 These	 results,	 however,	 do	 not	 clarify	 the	
influence	of	VHL-/-	myeloid	cells	on	allorecognition.	Nevertheless,	although	cardiac	allografts	
transplanted	 into	VHL-/-	 recipients	had	significantly	prolonged	survival,	 they	were	eventually	
rejected.	 This	 implies	 that	 allorecognition	 does	 occur	 in	 these	 recipients,	 possibly	 through	
memory	T	and	B	cells	and	small	numbers	of	APCs.2	Also,	the	almost	complete	lack	of	intragraft	






Figure	 33	 –	 Proposed	 progression	 of	 the	 alloimmune	 reaction	 in	 mVHL-/-	 cardiac	 allograft	 recipient	 mice:	 1)	 recipient	













allografts,	 and	 to	 induce	 a	 proinflammatory	milieu	 in	 the	 allograft	 at	 6h	 after	 reperfusion,	
characterized	by	increased	RANTES	and	VEGF-A	expression	and	decreased	anti-inflammatory	
HO-1	expression.	Also,	 at	5	days	after	 transplantation,	 the	allografts	 transplanted	 into	non-









which	 isoform	to	attribute	the	regulatory	effects	to.	Our	attempt	to	 investigate	this	 issue	 in	
vitro	produced	inconclusive	results.	On	one	hand,	myeloid-derived	cell	transduction	with	HIF-
1α	 induced	 the	MDSC	 and	M2	macrophage-specific	 transcription	 factor	 STAT3,	 and	 on	 the	
other	hand,	HIF-2α	transduction	promoted	the	expression	of	Arg1,	which	is	also	characteristic	






In	 summary,	 activation	 of	 the	HIF	 pathway	 (mVHL-/-)	 in	 heart	 transplant	 recipient	myeloid-
derived	 cells	 induced	 a	 regulatory	 phenotype	 that	 reduced	 ischemia-reperfusion	 and	 acute	
rejection,	and	prolonged	allograft	survival.	In	contrast	to	prior	belief,	myeloid-derived	cell	HIF-
1	expression	was	not	required	for	an	effective	inflammatory	response.	Thus,	our	results	suggest	
that	 genetic	 or	 pharmacological	 HIF	 activation	 in	 myeloid-derived	 cells	 may	 offer	 a	 novel	
therapeutic	 strategy	 to	 modulate	 recipient	 alloimmune	 responses	 after	 solid	 organ	










The	 future	 of	 heart	 transplantation	 lies	 in	 reducing	 the	 number	 of	 transplant	 recipients,	
increasing	the	donors,	and	maximizing	transplant	survival	and	patient	quality	of	life.	Advances	
in	genomics	and	proteomics	are	paving	the	way	for	personalized	transplantation.	The	discovery	
of	 new	 therapeutic	 targets	 and	markers	 for	 rejection	would	 enable	 targeted	 therapies	 and	
reduce	 the	 need	 for	 invasive	 endomyocardial	 biopsies	 for	 diagnosing	 transplant	 rejection,	
respectively.	Nonetheless,	biological	therapies	are	increasingly	common	in	the	clinic.487	Gene-
therapy	 can	 prolong	 or	 potentially	 prevent	 the	 alloimmune	 response	 by	 costimulatory	
blockade,	or	by	inducing	regulatory	leukocytes	in	the	recipient.488,489	Gene-editing	techniques,	
most	 notably	 CRISPR-Cas9	 has	 enabled	 the	 production	 of	 genetically	 engineered	 pigs.	 By	
removing	unwanted	infectious	genes	and	reducing	tissue	allogenicity,	xenotransplantation	is	
brought	closer	to	reality.490-492	Clinical	trials	with	Treg	cells	are	striving	to	reduce	the	dependence	














CMC	hypertrophy	and	 increased	susceptibility	 to	 ischemia-reperfusion	 injury	after	 long-
term	 transplant-specific	 overexpression,	 without	 any	 effect	 on	 capillary	 or	 arteriole	
density.	
	








Sydämensiirto	 on	 usein	 viimeinen	 vaikean	 sydäntaudin	 hoitomuoto.	 Alan	 kehityksistä	
huolimatta	 sydänsiirteen	 akuutti	 ja	 krooninen	 hyljintä	 ovat	 edelleen	 merkittäviä	
sydämensiirron	 pitkäaikaistuloksia	 heikentäviä	 tekijöitä.	 Hyljintään	 johtava	 patofysiologinen	
tapahtumaketju	saa	alkunsa	siirteen	luovuttajan	aivokuolemasta,	etenee	sydänsiirteen	ex	vivo-
kylmäsäilytyksen	 ja	 reperfuusion	 aikana,	 ja	 kulminoituu	 siirteeseen	 kohdistuvaan	
vastaanottajan	 immuunijärjestelmän	 aktivaatioon	 sekä	 siirteen	 vaskulopatiaan.	 Tässä	
väitöskirjatutkimuksessa	 arvioidaan	 Adeno-associated	 viruksen	 (AAV)	 tehoa	 ja	 turvallisuutta	
sydänsiirteen	 geeniterapiavektorina,	 selvitetään	 verisuonikasvutekijä	 vascular	 endothelial	
growth	 factor	 B:n	 (VEGF-B)	 osuutta	 sydänsiirteen	 iskemia-reperfuusiovauriossa	 (IRI),	 sekä	
hypoksiassa	 aktivoituvan	 transkriptiotekijä	 hypoxia-inducible	 factor:in	 (HIF)	 vaikutuksia	




sydänsiirteen	 sepelvaltimopuusto	 kullakin	 serotyypillä	 ja	 vertailemalla	 reportterigeenin	
ilmentymistä	ja	sydänsiirteen	tulehdusvastetta	keskenään.	VEGF-B:n	roolia	sydänsiirteen	IRI:ssa	
tutkittiin	 yli-ilmentämällä	 kasvutekijää	 sydänsiirteessä	 sekä	 transgeenisesti,	 että	 AAV-





tehokkain	 sydänsiirteen	 luovuttajalle	 suonensisäisesti	 annettuna.	 AAV9	 aiheutti	 lievän	
tulehduksellisen	 vasteen	 sydänsiirteissä.	 Pitkäaikainen,	 mutta	 ei	 lyhytaikainen	 VEGF-B	 yli-
ilmentäminen	 sydänsiirteessä	 aiheutti	 sydänlihassolujen	 hypertrofian	 ja	 korkeamman	
metabolisen	tarpeen,	altistaen	siten	sydänsiirrettä	IRI:n	haittavaikutuksille.	HIF-1α	sekä	HIF-2α	
aktivaatio	 sydänsiirteen	 vastaanottajan	 myeloidilinjan	 soluissa	 aiheutti	 näissä	












framsteg	 inom	 transplantationsmedicin	 belastar	 hjärttransplantatets	 avstötningsreaktion	
patienternas	 långtidsöverlevnad.	 Den	 händelsekaskad	 som	 leder	 till	 hjärttransplantatets	
avstötning	påbörjas	av	donatorns	hjärndöd,	progredierar	genom	ex	vivo	transport	av	organet,	
förvärras	 av	 reperfusion	 och	 kulminerar	 i	 hjärttransplantatets	 kroniska	 vaskulopati.	 I	 denna	
avhandling	 utvärderas	 Adeno-associated	 virus	 (AAV)	 effektivitet	 och	 säkerhet	 som	
hjärttransplantatets	genterapivektor.	Dessutom	undersöks	vaskulära	tillväxtfaktoren	vascular	
endothelial	growth	factor	B	(VEGF-B)	roll	i	hjärttransplantatets	ischemi-reperfusion	skada	(IRI)	
och	 transkriptionsfaktorn	 hypoxia-inducible	 factor	 (HIF)	 roll	 i	 inflammatoriska	 funktioner	 av	
myeloidlinjens	celler	i	hjärttransplantatets	avstötningsreaktion.	
	
I	 försökskonstellationen	 användes	 råttan	och	musen	 som	modell	 för	 hjärttransplantationer.	
Hjärttransplantatets	 koronarkärl	 perfuserades	 med	 AAV	 serotyperna	 2,	 8	 eller	 9.	
Långtidskinetiken	samt	säkerheten	jämfördes	genom	att	mäta	reportergenets	expression	och	
hjärttransplantatets	 inflammatoriska	 infiltrat.	 För	 att	 undersöka	 VEGF-B	 roll	 i	





koronarkärl,	 medan	 AAV9	 var	 mest	 effektiv	 efter	 intravenös	 administrering	 till	 donatorn.	
Serotyp	9	orsakade	en	lindring	inflammation	i	hjärttransplantatet.	Kronisk,	men	inte	kortvarig	
överexpression	 av	 VEGF-B	 i	 råttans	 hjärttransplantat	 orsakade	 kardiomyocyt	 hypertrofi	 och	





administrering	 i	 råttans	 experimentella	 modell	 för	 hjärttransplantation.	 Således	 betonar	
resultaten	administreringsvägen	av	AAV	virusvektorerna	i	genterapi	av	hjärttransplantat.	VEGF-
B	 verkar	 reglera	 hjärtans	 energikrav	 och	 kan	 således	 spela	 en	 viktig	 roll	 i	 hjärtans	
ischemitolerans.	 Transkriptionsfaktorerna	 HIF-1α	 och	 -2α	 reglerar	 den	 anti-inflammatoriska	







established	 research	group	as	a	 first-year	medical	 student,	providing	me	 the	 resources	and	
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